Human Pathology
Volume 36, Issue 5 , Pages 486-493 , May 2005

Human malignant melanoma: detection of BRAF- and c-kit–activating mutations by high-resolution amplicon melting analysis

Received 16 November 2004 ,Accepted 5 March 2005.

References 

  1. Hunter T, Quinn AM, Hanks SK. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science. 1988;241:42–52
  2. Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annu Rev Biochem. 2000;69:373–398
  3. Dibb NJ, Dilworth SM, Mol CD. Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat Rev. 2004;4:718–727
  4. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813–3825
  5. Houben R, Becker JC, Kappel A, Terheyden P, Brocker E, Goetz R, et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog. 2004;3:1–13
  6. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305:1163–1167
  7. Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116:855–867
  8. Garcia-Echeverria C, Fabbro D. Therapeutically targeted anticancer agents: inhibitors of receptor tyrosine kinases. Mini Rev Med Chem. 2004;4:273–283
  9. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4329–4342
  10. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New Engl J Med. 2002;346:645–652
  11. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500
  12. Lynch TJ, Bell DW, Sordellla R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl J Med. 2004;350:2129–2139
  13. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101:13306–13311
  14. Hauschild A, Weichenthal M, Balda B, et al. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment of resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol. 2003;21:2883–2888
  15. Sosman JA, Weeraratna AT, Sondak VK. When will melanoma vaccines be proven effective?. J Clin Oncol. 2004;22:387–389
  16. Hwu W, Krown SE, Menell JH, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol. 2003;21:3351–3356
  17. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954
  18. Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003;95:1878–1880
  19. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J. 2000;351:289–305
  20. Tuveson DA, Weber BL, Herlyn M. BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell. 2003;4:95–98
  21. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, et al. B-RAF is a therapeutic target in melanoma. Oncogene. 2004;23:6292–6298
  22. Hingorani SR, Jacobtz MA, Roberston GP, Herlyn M, Tuveson DA. Suppression of BRAFV599E in human melanoma abrogates transformation. Cancer Res. 2003;63:5198–5202
  23. Sumimoto H, Miyagishi M, Miyoshi H, Yamagat S, Shimizu A, Taira K, et al. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene. 2004;23:6031–6039
  24. Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer. 2001;8:219–225
  25. Kovach-Guerriere PM, Hunt EL, Patterson JW, Glembocki DJ, English JC, Wick MR. Primary melanoma of the skin and cutaneous melanomatous metastases: comparative histologic features and immunophenotype. Am J Clin Pathol. 2004;122:70–77
  26. Potti A, Hille RC, Koch M. Immunohistochemical determination of HER-2/neu overexpression in malignant melanoma reveals no prognostic value, while c-kit (CD 117) overexpression exhibits potential therapeutic implications. J Carcinog. 2003;2:8–14
  27. Willmore C, Holden JA, Zhou L, Tripp S, Wittwer CT, Layfield LJ. Detection of c-kit–activating mutations in gastrointestinal stromal tumors by high resolution amplicon melting analysis. Am J Clin Pathol. 2004;122:206–216
  28. Edwards RH, Ward MR, Medina CA, Brose MS, Volpe P, Nussen-Lee S, et al. Absence of BRAF mutations in UV-protected mucosal melanomas. J Med Genet. 2004;41:270–272
  29. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res. 2003;9:6483–6488
  30. Montone KT, van Bell P, Elenitsas R, Elder DE. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol. 1997;10:939–944
  31. Natali PG, Nicotra MR, Winkler AB, Cavaliere R, Bigotti A, Ullrich A. Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer. 1992;52:197–201
  32. Wardelmann E, Neidt I, Bierhoff E, Speidel N, Manegold C, Fisher H, et al. c-Kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant. Mod Pathol. 2002;15:125–136
  33. Gibson PC, Cooper K. CD117 (KIT): a diverse protein with selective applications in surgical pathology. Adv Anat Pathol. 2002;9:65–69
  34. Kemmer K, Corless CL, Fletcher JA, McGreevey L, Haley A, Griffith D, et al. Kit mutations are common in testicular seminomas. Am J Pathol. 2004;164:305–313
  35. Longley BJ, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu S-Z, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A. 1999;96:1609–1614
  36. Leslie MC, Bar-Eli M. Regulation of gene expression in melanoma: new approaches for treatment. J Cell Biochem. 2005;94:25–38
  37. Went PT, Dirnhofer S, Bundi M, et al. Prevalence of KIT expression in human tumors. J Clin Oncol. 2004;22:4514–4522

PII: S0046-8177(05)00166-8

doi: 10.1016/j.humpath.2005.03.015

Human Pathology
Volume 36, Issue 5 , Pages 486-493 , May 2005

Article Tools

* Image Usage & Resolution